Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals OyAnnouncement

Yesterday 08:45

Faron Pharmaceuticals Ltd | Company announcement | April 14, 2026 at 10:45:00
EEST

Capitalised terms used in this announcement have the meanings given to them in
the announcement made on 13 April 2026 at 14:00. EEST regarding the
amortisation payment and approval of share subscriptions based on special
rights, unless the context provides otherwise.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company developing novel immunotherapies,
has, as announced on 13 April 2026, approved the exercise of 3,572,851 Special
Rights entitling to 3,572,851 new Shares, for an aggregate subscription price
of EUR 1,613,499.51.

In total, 3,572,851 new Shares in the Company have today on 14 April 2026 been
registered in the Finnish Trade Register. The Shares rank pari passu in all
respects with the existing shares of the Company. Following the registration
of new Shares, the aggregate number of ordinary shares in the Company is
161,100,740.

Furthermore, as announced by the Company on 9 April 2026 and 13 April 2026,
the Company also expects to register today, 14 April 2026, a total of
41,944,771 offer shares issued as part of the rights issue. Following the
registration of such offer shares, the aggregate number of ordinary shares in
the Company will be 203,045,511. Shares held in treasury by the Company do not
confer a right to dividends or other shareholder rights. Following the
registration of the offer shares of the rights issue and new Shares as well as
completion of delivery of all offer shares of the rights issue, the Company
will have 3,530,573 shares in treasury and therefore, the total number of
voting rights in Faron is 199,514,938 (the “Number of Shares and Votes”). This
figure may be used by shareholders as the denominator for the calculations by
which they will determine whether they are required to notify an interest in,
or a change to their interest in, the Number of Shares and Votes of the
Company.

Trading in the new Shares is expected to commence on First North and AIM on 15
April 2026.

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     | kare.laukkanen@irpartners.fi         |
| Kare Laukkanen                      |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   | +1 847 791-8085                      |
| (Media)                             | alyssa.paldo@finnpartners.com        |
| Alyssa Paldo                        |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        | +44 (0) 207 213 0880                 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    | +358 (0)40 555 4727                  |
| (Certified Adviser on Nasdaq First  | +358 (0)50 553 8990                  |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company’s lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials as
a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com. (http://www.faron.com/)